Antibiotic Device for Osteomyelitis of the Extremities Pivotal Trial - Genex With Gentamicin.

NCT ID: NCT07270380

Last Updated: 2025-12-08

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 139 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-31
• Study Completion Date: 2028-07-31

Brief Summary

The purpose of this trial is to determine if genex with gentamicin (genex G) an antibiotic loaded bone void filler, works to treat and is a safe option as part of the surgical treatment of osteomyelitis in the extremities.

Detailed Description

This trial is a multi-center, single arm, historically controlled, pivotal device study.

All participants diagnosed with osteomyelitis of the extremities (Cierny-Mader Classification grades I-IV) can be considered. All participants will undergo surgical debridement and will receive genex with gentamicin (genex G) antibiotic loaded bone void filler as part of the surgical treatment of osteomyelitis of the extremities. Participants will receive antibiotics per site specific requirements as clinically indicated. All participants will be followed up for 24 Months.

Conditions

Osteomyelitis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single Arm

Participants will receive genex with Gentamicin, an antibiotic loaded bone void filler that supports bone healing, as part of the surgical treatment of osteomyelitis of the extremities.

Group Type: EXPERIMENTAL

genex with gentamicin (genex G)

Intervention Type: DEVICE

genex with gentamicin will be implanted during debridement surgery

Interventions

genex with gentamicin (genex G)

genex with gentamicin will be implanted during debridement surgery

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Patient with osteomyelitis of the extremities (for a minimum of 6 months) that requires surgical intervention (Cierny-Mader classification of osteomyelitis grades I-IV)

2. Patients at least 18 years of age *1

3. Patient willing and able to provide written informed consent

4. Patient geographically stable and able to comply with the required follow-up visits and testing schedule as assessed by the investigator

5. Ability to achieve adequate surgical soft tissue coverage of the wound (primary tissue closure or surgical reconstruction including local and free soft tissue transfer)

• 1 Patients between 18 and 22 years of age require confirmation of skeletal maturity as validated by radiographs of the bone to be treated.

Exclusion Criteria

1. Renal failure or documented chronic kidney disease with serum creatinine ≥3.5 mg/dL (309umol/L) or being treated with dialysis

2. Participants with a terminal or palliative diagnosis (e.g. terminal cancer diagnosis) deemed to have less than 1 year life expectancy by their health care team

3. Uncontrolled diabetes mellitus (haemoglobin A1c levels >10%)

4. Pre-existing calcium metabolism disorder

5. Women who are pregnant or breastfeeding or planning on becoming pregnant during the study (a pregnancy test will be done in women of childbearing potential at screening and on the day of surgery)

6. History of hypersensitivity or contraindication to the investigational device or any of its ingredients (calcium phosphate, β-tricalcium phosphate, and aminoglycoside antibiotics)

7. Participation in an investigational drug/device study (within the last 60 days) or prior enrolment to the ADOPT GG study

8. Clinically significant or unstable medical or surgical condition that in the investigators opinion may preclude safe and complete study participation (for example patients medically unfit for surgery, general anaesthesia, or any risk of significant blood loss resulting in significant risk to loss of life)

9. Current untreated malignant neoplasm(s), or current treatment with radiation therapy or chemotherapy

10. Current or recent history (within last 2 years) of active substance abuse (e.g. recreational drugs, narcotics, or alcohol) that meets DSM-5 severe criteria

11. Current user of any products containing nicotine

12. Currently incarcerated

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biocomposites Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Keira Watts, PHD

Role: STUDY_DIRECTOR

Biocomposites Ltd

Central Contacts

Keira Watts, PHD

Role: CONTACT

clinicaltrials@biocomposites.com

+44 (0)1782 338580

Simal Trikam

Role: CONTACT

strikam@mcra.com

Other Identifiers

201924

Identifier Type: -

Identifier Source: org_study_id